The Technical Analyst
PhaseBio Pharmaceuticals, [PHAS]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
PhaseBio Pharmaceuticals, Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0701
/ 4 apr 2024 @ 16:00
| RATING 2023-01-03 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | |
| Revenue | n/a | |||||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0300 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.0300 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ -0.0049 - 0.145 ( +/- 106.99%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-05-19 | Van Den Broek Richard | Buy | 3 750 | Common Stock |
| 2023-05-19 | Van Den Broek Richard | Sell | 3 750 | Restricted Stock Units |
| 2023-05-19 | Thorp Clay | Buy | 3 750 | Common Stock |
| 2023-05-19 | Thorp Clay | Buy | 3 750 | Restricted Stock Units |
| 2023-05-19 | Humphries William D. | Buy | 2 538 | Common Stock |
| INSIDER POWER |
|---|
| -88.97 |
| Last 98 transactions |
| Buy: 2 306 852 | Sell: 1 915 751 |
Forecast:
01:40 - $0.408
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0701 (0.00% ) |
| Volume | 8.56 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PHAS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PHAS
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Latest Press Releases
2022-10-24 08:00:00 - Press Release
Phasebio Plans For Near-term Sale Using Structured Process Through Chapter 11 Of U.s. Bankruptcy Code
Malvern, pa.
2022-08-12 08:30:00 - Press Release
Phasebio Pharmaceuticals Reports Second Quarter 2022 Financial Results And Recent Business Highlights
Malvern, pa. & san diego--(business wire)--phasebio pharmaceuticals, inc. (nasdaq: phas), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended june 30, 2022, and provided an update on corporate activities. “the second quarter of 2022 marked a period of continued progress for phasebio,” said jonathan mow, chief executive officer of phasebio pharmaceuticals. “following a successful meeting with the u.s. food and drug administration (fda) during our pre-biologics license application (pre-bla) meeting earlier this year and as previously disclosed, we have been focused on clinical development and regulatory efforts to support a planned bla submission for our lead program, bentracimab, in the fourth quarter of this year...
2022-05-16 06:00:00 - Press Release
Phasebio Announces Successful Pre-bla Meeting With U.s. Fda For Bentracimab
Malvern, pa. & san diego--(business wire)--phasebio pharmaceuticals, inc. (nasdaq: phas), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced the completion of a successful type b pre-biologics license application (pre-bla) meeting with the u.s. food and drug administration (fda) for bentracimab, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in patients presenting with uncontrolled bleeding or in need of surgery. based on this pre-bla meeting and the formal written minutes received from the fda, phasebio intends to submit the bla for bentracimab by early in the fourth quarter of 2022...
2022-05-16 06:00:00 - Press Release
Phasebio Pharmaceuticals Reports First Quarter 2022 Financial Results And Recent Business Highlights
Malvern, pa. & san diego--(business wire)--phasebio pharmaceuticals, inc. (nasdaq: phas), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the first quarter ended march 31, 2022, and provided an update on corporate activities. “the first quarter of 2022 was a period of significant momentum for phasebio, as we continued to advance our pipeline and lay the groundwork for the commercialization of bentracimab in the united states. our progress was driven primarily by the successful completion of a type b pre-bla meeting with the fda, which positions us to submit our bla early in the fourth quarter of this year,” said jonathan mow, chief executive officer of phasebio pharmaceuticals...
2022-04-07 16:00:00 - Press Release
Phasebio Pharmaceuticals To Participate In The 21st Annual Needham Healthcare Conference
Malvern, pa. & san diego--(business wire)--phasebio pharmaceuticals to participate in the 21st annual needham healthcare conference
Latest News
2022-10-17 19:41:22 - 24/7 Wall Street
These Were The Five Best And Worst Performing Healthcare Stocks In September 2022
September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.
2022-08-12 11:17:33 - Zacks Investment Research
PhaseBio Pharmaceuticals (PHAS) Reports Q2 Loss, Lags Revenue Estimates
PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of -3.03% and 91.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-05-16 08:17:03 - Zacks Investment Research
PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates
PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of 65.67% and 98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2021-12-21 12:43:57 - Benzinga
PhaseBio Pulls Plug On Mid-Stage Hypertension Asset
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) is voluntarily ending its Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension (PAH). The decision follows COVID-19 impacts on manufacturing, associated drug supply, and enrollment rate in the study.
2021-11-15 14:32:19 - Benzinga
PhaseBio's Shares Slide As Antiplatelet Candidate Shows Higher Rates Of Side Effect
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced interim results from the REVERSE-IT Phase 3 trial of bentracimab to reverse the antiplatelet effects of ticagrelor. The trial included patients with urgent surgery or an invasive procedure or experiencing uncontrolled major or life-threatening bleeding.
2021-11-10 18:19:03 - Zacks Investment Research
PhaseBio Pharmaceuticals (PHAS) Reports Q3 Loss, Lags Revenue Estimates
PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of -6.45% and -87.43%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
2021-11-03 10:10:52 - Benzinga
PhaseBio's Bentracimab Reverses Ticagrelor-Associated Antiplatelet Activity In Mid-Stage Study
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced topline data from its Phase 2b trial of bentracimab in healthy, older volunteers 50-80 years old. The trial in 150 subjects receiving bentracimab and 50 subjects receiving placebo after all were pretreated with dual antiplatelet therapy composed of AstraZeneca Plc's (NASDAQ: AZN) Brilinta (ticagrelor) and low-dose aspirin.
2021-10-31 10:30:00 - PennyStocks
5 Penny Stocks To Watch For November With Potential Biotech Catalysts
Biotech penny stocks to watch with upcoming events this week. The post 5 Penny Stocks To Watch For November With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-10-07 12:11:02 - Zacks Investment Research
Do Options Traders Know Something About PhaseBio Pharmaceuticals (PHAS) Stock We Don't?
Investors need to pay close attention to for PhaseBio Pharmaceuticals (PHAS) stock based on the movements in the options market lately.
2021-08-31 16:00:00 - Business Wire
PhaseBio Pharmaceuticals to Present at 23rd Annual H.C. Wainwright Global Investment Conference
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Pharmaceuticals to Present at 23rd Annual H.C Wainwright Global Investment Conference